(ELVA) Electrovaya Common Shares - Overview
Stock: Lithium-Ion Batteries, Battery Systems, High Voltage, Solid State
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 120% |
| Relative Tail Risk | -21.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.97 |
| Alpha | 237.43 |
| Character TTM | |
|---|---|
| Beta | 0.716 |
| Beta Downside | 0.430 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.19% |
| CAGR/Max DD | 0.37 |
Description: ELVA Electrovaya Common Shares January 17, 2026
Electrovaya Inc. (NASDAQ: ELVA) designs, develops, manufactures, and sells lithium-ion batteries, battery-management systems, and related products for energy-storage, clean-transport, and specialty markets across North America.
The firm’s product portfolio spans low- and high-voltage “infinity” battery systems, solid-state battery prototypes, and turnkey solutions for material-handling equipment (e.g., forklift batteries), robotics, defense, construction, and heavy-duty electric vehicles such as buses and trucks.
Key recent metrics (Q4 2023): revenue of $12.4 million, a 22 % YoY increase driven by higher demand for industrial energy-storage contracts; cash on hand of $28 million, providing ~18 months of runway at current burn rates; and a gross margin of 18 % after scaling up its high-voltage module line.
Sector drivers that directly impact ELVA include the accelerating adoption of electrified material-handling fleets (projected CAGR ≈ 15 % through 2028) and the tightening global lithium-ion supply chain, which has pushed lithium carbonate prices up ~30 % YoY, favoring vertically integrated manufacturers.
Analysts note that ELVA’s ability to commercialize solid-state cells remains a high-risk, high-reward catalyst; success would markedly improve energy density and safety, potentially unlocking new defense and aerospace contracts.
For a deeper, data-driven look at ELVA’s valuation assumptions and scenario analysis, the ValueRay platform offers transparent models you can explore at your own pace.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 3.36m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA -17.89 > 1.0 |
| NWC/Revenue: 50.14% < 20% (prev 1.98%; Δ 48.16% < -1%) |
| CFO/TA 0.01 > 3% & CFO 836.2k > Net Income 3.36m |
| Net Debt (16.2m) to EBITDA (5.59m): 2.90 < 3 |
| Current Ratio: 4.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.1m) vs 12m ago 23.80% < -2% |
| Gross Margin: 30.62% > 18% (prev 0.29%; Δ 3033 % > 0.5%) |
| Asset Turnover: 123.0% > 50% (prev 113.7%; Δ 9.30% > 0%) |
| Interest Coverage Ratio: 1.41 > 6 (EBITDA TTM 5.59m / Interest Expense TTM 2.88m) |
Altman Z'' -2.14
| A: 0.50 (Total Current Assets 42.0m - Total Current Liabilities 10.1m) / Total Assets 63.9m |
| B: -1.97 (Retained Earnings -125.9m / Total Assets 63.9m) |
| C: 0.08 (EBIT TTM 4.07m / Avg Total Assets 51.7m) |
| D: 0.45 (Book Value of Equity 14.9m / Total Liabilities 32.8m) |
| Altman-Z'' Score: -2.14 = D |
Beneish M 0.50
| DSRI: 1.03 (Receivables 16.5m/11.3m, Revenue 63.6m/44.9m) |
| GMI: 0.96 (GM 30.62% / 29.30%) |
| AQI: 6.40 (AQ_t 0.14 / AQ_t-1 0.02) |
| SGI: 1.42 (Revenue 63.6m / 44.9m) |
| TATA: 0.04 (NI 3.36m - CFO 836.2k) / TA 63.9m) |
| Beneish M-Score: 0.50 (Cap -4..+1) = D |
What is the price of ELVA shares?
Over the past week, the price has changed by -18.28%, over one month by +1.96%, over three months by +71.51% and over the past year by +255.42%.
Is ELVA a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.8 | -0.6% |
| Analysts Target Price | 8.8 | -0.6% |
| ValueRay Target Price | 10.3 | 16.7% |
ELVA Fundamental Data Overview February 02, 2026
P/E Forward = 64.9351
P/S = 7.9634
P/B = 15.9219
P/EG = 0.9649
Revenue TTM = 63.6m USD
EBIT TTM = 4.07m USD
EBITDA TTM = 5.59m USD
Long Term Debt = 20.7m USD (from longTermDebt, last quarter)
Short Term Debt = 715.7k USD (from shortTermDebt, last quarter)
Debt = 22.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.2m USD (from netDebt column, last quarter)
Enterprise Value = 523.8m USD (508.3m + Debt 22.6m - CCE 7.01m)
Interest Coverage Ratio = 1.41 (Ebit TTM 4.07m / Interest Expense TTM 2.88m)
EV/FCF = -52.58x (Enterprise Value 523.8m / FCF TTM -9.96m)
FCF Yield = -1.90% (FCF TTM -9.96m / Enterprise Value 523.8m)
FCF Margin = -15.67% (FCF TTM -9.96m / Revenue TTM 63.6m)
Net Margin = 5.29% (Net Income TTM 3.36m / Revenue TTM 63.6m)
Gross Margin = 30.62% ((Revenue TTM 63.6m - Cost of Revenue TTM 44.1m) / Revenue TTM)
Gross Margin QoQ = 30.17% (prev 30.80%)
Tobins Q-Ratio = 8.19 (Enterprise Value 523.8m / Total Assets 63.9m)
Interest Expense / Debt = 4.28% (Interest Expense 965.2k / Debt 22.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = 3.21m (EBIT 4.07m * (1 - 21.00%))
Current Ratio = 4.16 (Total Current Assets 42.0m / Total Current Liabilities 10.1m)
Debt / Equity = 0.72 (Debt 22.6m / totalStockholderEquity, last quarter 31.1m)
Debt / EBITDA = 2.90 (Net Debt 16.2m / EBITDA 5.59m)
Debt / FCF = -1.63 (negative FCF - burning cash) (Net Debt 16.2m / FCF TTM -9.96m)
Total Stockholder Equity = 23.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.50% (Net Income 3.36m / Total Assets 63.9m)
RoE = 14.20% (Net Income TTM 3.36m / Total Stockholder Equity 23.7m)
RoCE = 9.15% (EBIT 4.07m / Capital Employed (Equity 23.7m + L.T.Debt 20.7m))
RoIC = 7.90% (NOPAT 3.21m / Invested Capital 40.6m)
WACC = 8.33% (E(508.3m)/V(530.8m) * Re(8.55%) + D(22.6m)/V(530.8m) * Rd(4.28%) * (1-Tc(0.21)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.56%
Fair Price DCF = unknown (Cash Flow -9.96m)
EPS Correlation: 73.40 | EPS CAGR: 42.39% | SUE: -0.06 | # QB: 0
Revenue Correlation: 64.12 | Revenue CAGR: 110.2% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=-0.004 | Revisions Net=-2 | Analysts=5
EPS current Year (2026-09-30): EPS=0.14 | Chg30d=+0.001 | Revisions Net=-5 | Growth EPS=+68.8% | Growth Revenue=+32.0%
EPS next Year (2027-09-30): EPS=0.32 | Chg30d=-0.073 | Revisions Net=-4 | Growth EPS=+134.6% | Growth Revenue=+47.5%